Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$27.51 USD
-0.55 (-1.96%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $27.51 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
APLS 27.51 -0.55(-1.96%)
Will APLS be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for APLS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for APLS
Apellis Stock Down as Eye Drug Faces Third CHMP Rejection in the EU
Why Is SpringWorks Therapeutics (SWTX) Up 11.7% Since Last Earnings Report?
APLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia (ACAD) Up 10% Since Last Earnings Report: Can It Continue?
Rocket Pharmaceuticals (RCKT) Down 10.6% Since Last Earnings Report: Can It Rebound?
Apellis (APLS) Q2 Earnings Beat, Syfovre Sales Drive Revenues
Other News for APLS
Apellis: Weighing Syfovre's Rapid Expansion Against Risks In The GA Market (Rating Upgrade)
Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion
Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)
Hartford MidCap Fund Q2 2024 Commentary
Catalyst Watch: Tesla deliveries, Nike earnings, port strike threat and the jobs report